Paul Simon told us some time ago that we lived in an age of miracle and wonder. The rest of his lyrics for The Boy in the Bubble, however, made it clear he did not mean the kind bestowed upon us by supernatural forces. He meant the kind we devised ourselves. He meant technology, and he was right- for better or for worse.
IBM Watson may have shifted from the all-knowing doctor to patient, ending up in critical condition in the Information Care Unit (ICU).
There can be no better insight into Pharma’s digital ambition than building a digital agency from scratch with pharmaceutical companies as the core client base. I have been working in pharma my whole career (now some 19 years) and feel very fortunate to have been around at a time of unprecedented change as technology has fundamentally impacted all aspects of the pharmaceutical business; from drug discovery and clinical trial development, through to the very nature of the product as health technology builds an evidence base and the focus moves from illness to wellness.
Innovation starts with the right mindset. Doctors who are considering a side gig or an alternative non-clinical career, have a hard time getting their heads around the entrepreneurial mindset. There is a difference between the clinical mindset and the entrepreneurial mindset.
When people think of bipolar disorder they often think of mania and the extremes that can happen. However, bipolar disorder exists on a spectrum with 2 main types: Bipolar 1 and Bipolar 2. Bipolar 2 is a milder (yet still uncomfortable!) form of bipolar. People with Bipolar 2 Disorder experience hypomania instead of mania. So what is hypomania and how is it different from mania?
Biologics and biosimilars are all we’re hearing about now a days. It’s like we’re back in the early-mid 1900s when we were still trying to figure out how to deal with generic medications. A biosimilar drug is created based off an original (or Brand) biological drug. But, why aren’t we just calling it a generic drug?
The relentless search for innovation is the rallying call of industry today, and big pharma is no different. Thousands of employees are commonly huddled together in impressive conference rooms and amphitheaters and the key task is send down from on high: INNOVATE. Then, those huddled masses, sometimes even struck with the fear of obsolescence, look to each other in hopes of finding that magic.